Real-world experience on the effectiveness and tolerability of apremilast in patients with plaque psoriasis in India
Introduction: Apremilast, a phosphodiesterase-4 inhibitor, has been recently approved for the management of plaque psoriasis in India in 2017. However, no real-world experience pertaining to apremilast has been documented. Materials and Methods: A retrospective review of medical records was conducte...
Main Authors: | Shrichand Parasramani, Jayakar Thomas, Leelavathy Budamakuntla, Dhiraj Dhoot, Hanmant Barkate |
---|---|
Format: | Article |
Language: | English |
Published: |
Wolters Kluwer Medknow Publications
2019-01-01
|
Series: | Indian Journal of Drugs in Dermatology |
Subjects: | |
Online Access: | http://www.ijdd.in/article.asp?issn=2455-3972;year=2019;volume=5;issue=2;spage=83;epage=88;aulast=Parasramani |
Similar Items
-
Real-world insight on apremilast therapy in patients with plaque psoriasis: Indian experience
by: Abhishek De, et al.
Published: (2020-01-01) -
Apremilast titration: Real-world indian experience
by: Abhishek De, et al.
Published: (2021-01-01) -
Apremilast generic for the treatment of active psoriatic arthritis: A single-center real-life experience from India
by: Sanjiv Amin, et al.
Published: (2020-01-01) -
The Use of Apremilast in Psoriasis: An Indian Perspective on Real-World Scenarios
by: Rajagopalan M, et al.
Published: (2021-08-01) -
Apremilast coadministered with secukinumab for safe and effective control of psoriasis with resultant reduction of maintenance dose of the biologic
by: Abhishek De, et al.
Published: (2019-01-01)